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Terminal complement components comprise the final 5 components 
of the complement cascade (C5 to C9). All combine on antibody-
bound (sensitised) target-cell surfaces to produce the membrane 
attack complex (MAC) which is potentially lytic for bacteria, 
viruses and mammalian cells. MAC formation is not possible if any 
terminal components are absent. Patients genetically deficient in any 
component are typically identified when they present with recurrent 
meningococcal disease (MD). Infections are endemic in South Africa 
(SA) with 2 432 cases reported over a 5-year period (2006 - 2010).1 
The last epidemic, related to the emergence of serogroup W135,2 
occurred in 2005/6 in Gauteng; infection rates in the province 
increased to 3.98/100 000 from 0.81/100 000 in 2000. Within this 
period, the Western Cape experienced a decrease in cases from 
2.48/100 000 to 1.51/100 000.  
About 50 South Africans have been diagnosed with C6Q0 in the 
Western Cape. The original diagnosis depended on a C6 haemolytic 
assay.3 C6Q0 subjects have a complete lack of functional C6 – distinct 
from patients with subtotal C6 deficiency (C6SD), where a small amount 
of C6 activity remains.4 Four single base pair deletions, each causing 
a frame-shift mutation, have been found to be responsible for C6Q0;5 
the patients were either coloured or black. Three of the mutations 
were first reported in African-Americans, but the fourth (828delG) 
was first reported in coloured and black individuals.5-7 Molecular-level 
investigations of 2 SA families with C5 deficiency have been performed. 
Preliminary data indicate 3 different C5 mutations in the Cape region.8 
Both C5D and C6Q0 can be caused by the identical mutation on both 
alleles (homozygous) or by 2 different mutations with 1 mutation in each 
allele (compound heterozygous) on the respective gene.
It is recognised that people with deficiencies of terminal 
complement components have increased susceptibility to MD.9 
However, it is not known how many MD cases in SA are complement 
deficient. Repeated infections can have long-term consequences 
including failure to achieve at school, severe headaches, the need for 
sheltered employment, deafness, and the loss of limbs or digits due to 
intravascular blood clotting during acute infection.10 
In this study we investigated 109 Western Cape patients with 
culture-confirmed MD; we tested for the 7 molecular defects 
discussed above (3 in the C5 gene and 4 in the C6 gene).
Methods
The study received ethical approval from the University of Cape 
Town (REC:REF 259:2007 and approved amendment dated 16 June 
2010).
C5 and C6 mutation frequency 
Traceable patients diagnosed with culture-confirmed invasive 
Neisseria meningitidis infection by the National Health Laboratory 
Service (NHLS) in the Western Cape within the preceding 5 years 
were included in the study. Race classification for black patients 
was by name or personal contact. Coloured race was determined by 
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personal contact or information recorded by a health professional. 
Five white patients were investigated but excluded from the study. 
Ethylenediaminetetraacetic acid (EDTA) blood samples were taken 
from each patient; deoxyribonucleic acid (DNA) was extracted from 
buffy coat or blood spots. DNA samples were tested for the 2 known 
C5 gene mutations (Q19X, R1476X) and a third (A252T) that we found 
associated with C5D.8,11 Four C6 gene mutations (821delA, 828delG, 
1138delC and 1879delG), all known to be responsible for C6Q0 in the 
Western Cape, were examined. The regions of interest were amplified 
by polymerase chain reaction (PCR) and the mutations detected by 
allele-specific primers or restriction enzyme digestion. All positive 
C5D or C6Q0 results were confirmed by DNA sequencing.5,8,12
Frequency controls: 1 500 newborn cord bloods were tested for 
C5 mutation A252T (750 black, 750 coloured); 400 cord bloods were 
tested for C5 mutations Q19X and R1476X (200 black, 200 coloured); 
and 180 white patient samples were tested for all 7 mutations. 
C5 and C6 protein levels
C5 protein levels were detected with a specific C5 enzyme-linked 
immunosorbent assay (ELISA) employing the native restricted 
monoclonal anti-C5 antibody N19-8 and biotinylated goat anti-C5 
antibody (in-house).13 C6 protein levels were not determined 
because earlier studies showed that homozygosity, or compound 
heterozygosity, of any 2 of the 4 specific C6 defects resulted in a 
complete lack of functional C6 activity.5,11
Results
Mutation frequency of C5 and C6 genes 
A total of 109 patients (or the parents in the case of one infant) with 
culture-positive MD agreed to participate in the study. C5D or C6Q0 
was detected in 21.7% of black (N=46) and 6.3% of coloured (N=63) 
patients (Table 1). 
Three black patients were homozygous for C5 mutation A252T. No 
patient tested positive for C5 mutations Q19X and R1476X. No coloured 
patient tested positive for C5D. All 4 previously reported C6 mutations 
(821delA, 828delG, 1138delC and 1879delG) were observed. One 
patient was homozygous for 828delG and another for 1138delC. Nine 
patients were compound heterozygous for all 4 mutations in various 
combinations; 7 of these patients were coloured and 4 were black. 
Controls: C5 mutation A252T was found in 55 (45 black and 10 
coloured) of 1 500 (750 black, 750 coloured) newborn cord bloods tested 
(Table 2); no mutant alleles were identified in 400 controls (200 black, 
200 coloured) tested for Q19X and R1476X; none of the 7 defects were 
detected in 180 white patient controls tested. These mutations appear to 
be rare in whites (the control sample size was relatively small). 
C5 protein levels
C5 levels were tested in 2 of the 3 homozygous C5D-A252T patients 
(the third died of MD and only DNA was available). ELISA-detected 
C5 levels were very low (approximately 1 - 2% of normal).
Discussion
Of the 109 MD patients who presented during the preceding 5 
years, 2.7% were C5D and 10.1% were C6Q0; 46 were black patients, 
including 3 C5D (6.5%) and 7 C6Q0 (15.2%); 63 were coloured 
patients, including 4 C6Q0 (6.3%; none were C5D). A preliminary 
survey of C5 genetic defects in neonates born in 2002/3, showed 
expected homozygous C5D-A252T in 1/1 111 black neonates and 
1/22 500 coloured neonates.8 
It is recognised that C5 deficiency increases susceptibility to 
MD.11,14,15 We found a significantly increased number of C5-A252T 
alleles in MD patients compared with the general black population 
(p<0.005). One heterozygous C5-A252T and no C5-A252T 
homozygous individuals were found in the coloured MD patients. 
This may be explained by the small sample number (63 patients) and 
the low frequency of A252T in the general population.
Based on previous findings in neonates born in 2002/3,10 the 
predicted C6Q0 frequency was 1/2 873 in blacks and 1/1 600 in 
coloureds. Yet, we found a much higher prevalence of C6Q0 in black 
v. coloured MD patients, suggesting a higher susceptibility of the 
former to MD. This predisposition to MD may be attributed to social 
factors, poor living conditions and overcrowding.
Based on 2001 census data, there are approximately 1.2 million 
black and 2.4 million coloured persons in the Western Cape.16 We 
calculated that approximately 2 000 individuals are C6Q0 and at 
increased risk of MD. Newborn C6Q0 screening is not available; 
therefore, it is not possible to speculate as to the percentage of 
complement-deficient patients that suffer MD. Data from families of 
C6Q0 patients show that not all C6Q0 siblings suffer MD before the 
age of 20 years, suggesting that susceptibility is variable.10
A single MD episode can result in serious long-term sequelae; we 
recently showed that 73% of C6Q0 patients who suffered recurrent 
MD developed serious illness or died.10 To prevent recurrence, it is 
essential that all identified C5D and C6Q0 patients can access regular 
effective antibiotic prophylaxis and vaccination is being considered. 
Problematically, in the Western Cape approximately 50% of isolated 
strains are group B,17 for which there is, as yet, no vaccine. Nevertheless, 
a quadrivalent vaccine (such as Menveo) containing Groups A, C, Y 
and W135 polysaccharides could be extremely beneficial. A factor 
H-binding protein, or other protein vaccine, for immunity to Group B 
and possibly other strains, is currently under investigation.18
One test available for complement deficiency, although only in 
some centres, involves total haemolytic complement screening. 
This requires freshly prepared serum samples to be frozen at -80ºC 
until the assay is performed; this is not ideal for screening patients 
in rural locations. Screening for C5 and C6 deficiency in this study 
was performed genetically. Samples could be transported at room 
temperature and DNA could be prepared from blood spots or any 
blood sample (EDTA blood was preferred). This allowed us to study 
samples from all over the province. 
It is not known whether gene frequencies found in the Western 
Cape are representative of other black populations across the country. 
The majority of blacks in the province are reportedly Xhosa;16 ideally, 
future work should include people from different regions of SA.
Conclusion
We recommend screening for the common C5D and C6Q0 genetic 
defects in black and coloured patients presenting with meningococcal 
meningitis in the Western Cape. White patients can be assessed with 
the total haemolytic complement screen. We hope that the genetic 
test for C5D and C6Q0 will eventually be available throughout SA. 
Prophylactic treatment and/or vaccination is/are recommended for 
patients at risk for MD. 











Black 46 3 (6.5) 7 (15.2) 10 (21.7)
Coloured 63 0 (0) 4 (6.3) 4 (6.3)
Total 109 3 (2.7) 11 (10.1) 14 (12.8)
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Table 2. Mutation frequency of C5 defects in black and coloured patient controls
Black Coloured
C5 mutation Q19X A252T R1476X Q19X A252T R1476X
Alleles tested (N) 400 1 500 400 400 1 500 400
Positive alleles (n) 0 45 0 0 10 0
Frequency (%) 0 3 0 0 0.66 0
Estimated homozygosity 1/1 111 1/22 500
